Conference Visibility Underscores Rivermark Medical’s Progress in BPH Therapy Development

According to a recent LinkedIn post from Rivermark Medical, the company was featured at the EAU 2026 urology meeting, where its clinical development work was presented in two separate sessions by Dean Elterman, M.D. The post suggests Rivermark is advancing a “one-of-a-kind” treatment for benign prostatic hyperplasia (BPH) and is already promoting engagement around the AUA 2026 meeting in Washington, D.C.

The company’s presence in multiple scientific sessions at a major urology congress may indicate growing clinical traction and peer interest in its BPH program. For investors, this visibility could signal progress toward later-stage clinical validation, potential partnering discussions, and future commercialization opportunities in a large, established therapeutic market.

By highlighting ongoing development work rather than commercial milestones, the post implies Rivermark remains in a clinical or pre-commercial phase. Continued participation in high-profile conferences such as EAU and AUA could help the company build physician awareness, support future regulatory pathways, and strengthen its competitive position in the BPH treatment landscape.